ITEL

What ITEL does

ITEL Telecomunicazioni S.r.l. is an Italian healthcare-engineering company founded in 1982 by Leonardo Diaferia and headquartered in Ruvo di Puglia, Italy. The company operates as a multi-division platform built on electromagnetic-wave, field, and radiation engineering applied to medical technology, organized across four operating divisions — ITELPHARMA (GMP-certified radiopharmaceutical production authorized by AIFA), ITEL Diagnostic (design and shielding of diagnostic-imaging facilities), ITEL EMC (electromagnetic compatibility testing for CE marking), and the LinearBeam spin-off (ERHA linear proton accelerator development, funded with €14.9M from the EIB via MIUR/Equiter). Corporate headcount grew to the 101–250 range on the back of approximately 70 new hires in 2022.

Name

ITEL

Legal name

ITEL Telecomunicazioni S.r.l.

Website

https://itelte.it

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

101–250 employees

Short description

ITEL Telecomunicazioni S.r.l. is an Italy-based healthcare engineering group operating radiopharmaceutical production, hospital facility design, EMC testing, and linear proton accelerator development through wholly-owned divisions including ITELPHARMA and the LinearBeam spin-off.

Ownership category

akta.pro rank

Product category

Medical Technology and Radiopharmaceuticals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Irradiation Apparatus Manufacturing (334517), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Radiopharmaceutical manufacturing
• Proton therapy systems
• Medical imaging equipment
• Electromagnetic compatibility testing
• Healthcare engineering services

Headquarters

HQ city

Ruvo Di Puglia

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Radiopharmaceutical Production and Distribution: Production and distribution of radioactive molecules for diagnostic imaging, primarily for oncological and neurodegenerative diseases. Manufactured at GMP-certified facility in Ruvo di Puglia and distributed to hospitals and healthcare facilities across Italian regions.
2. Engineering Services for Healthcare Facilities: Turnkey solutions for hospital departments including design, radiation shielding, and complete healthcare facility construction. Includes GMP certification support services for radiopharmacy compliance.
3. Medical Equipment Manufacturing: Sale of proton therapy systems (ERHA), patient positioning equipment, and diagnostic imaging technology to hospitals and research institutions.
4. Electromagnetic Compatibility Testing: EMC laboratory testing services for CE marking of electrical and electronic products, serving manufacturers requiring regulatory compliance certification.
5. Licensing and Technology Transfer: Licensing of proprietary radiopharmaceutical molecules (18F-JK-PSMA-7, 18F-DOPA) and technology transfer agreements for pharmaceutical production. Includes collaboration with universities and research institutions for patent development.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

ITEL Telecomunicazioni S.r.l. designs, manufactures, and distributes medical technology products and engineering services for healthcare facilities. The company operates four main divisions: Itelpharma (GMP-certified production of radiopharmaceuticals and PET diagnostic tracers), LinearBeam (development of the ERHA linear proton accelerator for cancer treatment), ITEL Diagnostic (design and construction of diagnostic imaging facilities and radiation shielding), and ITEL EMC (electromagnetic compatibility testing for CE marking). Itelpharma also licenses proprietary radiotracer molecules such as 18F-JK-PSMA-7 and 18F-DOPA for hospital-based production.

Product overview

ITEL Telecomunicazioni S.r.l. is an Italian healthcare technology group headquartered in Ruvo di Puglia, operating as a multi-division platform company. The portfolio consists of five main divisions/products: (1) LinearBeam / ERHA, a spin-off developing the world's first linear proton accelerator for cancer therapy (not yet clinically approved); (2) ITELPHARMA, the GMP-certified radiopharmaceutical division producing and distributing radioactive diagnostic tracers (18F-JK-PSMA-7, 18F-DOPA, and others) to hospitals and nuclear medicine departments across Italy; (3) ITEL Diagnostic, designing and constructing diagnostic imaging facilities and radiation shielding; (4) ITEL EMC, providing electromagnetic compatibility testing for CE marking; and (5) multiple R&D projects (PROMISE, RAISE, HELIUM 3, RPPS, MASSIME, LOGIN, Bioimaging Cluster, EURO6 NOx Sensors, Progetto DIPG) spanning radiopharmaceutical development, proton therapy robotics, lung MRI imaging, mechatronics safety, logistics, and industrial sensing. The divisions share a unified engineering platform focused on wave, field, and electromagnetic radiation science applied to healthcare.

Differentiator

Problem solved

Functional benefit

Brands

• LinearBeam: Spin-off company developing ERHA (Enhanced Radiotherapy with HAdrons) - linear proton accelerator technology for cancer treatment.
• Itelpharma
• ITEL Diagnostic
• ITEL EMC

Products and services

• ERHA (Enhanced Radiotherapy with HAdrons) Proton Therapy System Linear proton accelerator system for proton therapy cancer treatment, integrating anthropomorphic robots for patient positioning and dedicated treatment planning software. World's first linear proton accelerator, currently under development and not yet approved for clinical use. Targeted at cancer treatment centers and research hospitals.
• Itelpharma Radiopharmaceutical Production Service Contract manufacturing and distribution of radiopharmaceuticals (PET diagnostic tracers) for hospitals and nuclear medicine departments, produced at AIFA GMP-certified facility. Operated as ITEL's radiopharmaceutical division, serving oncological and neurodegenerative disease diagnostics.
• ITEL Diagnostic Facility Design and Construction Turnkey engineering service for design, radiation shielding (ionizing and non-ionizing), and construction of complete diagnostic imaging departments and healthcare facilities. Targeted at hospitals and healthcare centers requiring complex imaging infrastructure.
• ITEL EMC Electromagnetic Compatibility Testing
• 18F-JK-PSMA-7 Radiotracer Fluorine-18 labeled PET radiotracer for diagnostic imaging of prostate cancer, binding to prostate-specific membrane antigen (PSMA). Demonstrated over 95% positive predictive value in clinical studies. Licensed exclusively for Italy, Spain, and Portugal.
• 18F-DOPA Radiotracer Formulation Patent-protected stable formulation of 18F-DOPA for early diagnosis of Parkinson's disease and neuroendocrine tumors via PET imaging. Jointly patented with University of Bari.
• RPPS Robotized Patient Positioning System
• Hyperpolarized Helium-3 (3He) Lung MRI System

Quantifiable outcome

• 18F-JK-PSMA-7 radiotracer achieves over 95% positive predictive value in prostate cancer detection
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• IRCCS Don Calabria (Ospedale Sacro Cuore Don Calabria)coreStrategic or Co-development Partner · 15 February 2021Multi-year collaboration agreement for radiopharmacy GMP certification support. ITEL will provide technical expertise for AIFA GMP certification, technology transfer, and personnel training. Once certified, IRCCS will produce radiopharmaceuticals for Northern Italy under Itelpharma commercialization.
• Max Planck Innovation InstitutecoreStrategic or Co-development Partner · 15 February 2021Licensor of 18F-JK-PSMA-7 radiotracer patent for prostate cancer imaging. Provides exclusive license to Itelpharma alongside C-Spect for Italy, Spain, and Portugal markets.
• University of ColognecoreStrategic or Co-development Partner · 15 February 2021Co-patent holder with Max Planck Innovation for 18F-JK-PSMA-7 radiotracer. Contributed to discovery of molecule for PSMA-targeted prostate cancer imaging.
• Università degli Studi di Bari - Department of PharmacycoreStrategic or Co-development Partner · 2 February 2021Research collaboration on DIPG (Diffuse Intrinsic Pontine Glioma) pediatric brain tumor project. Professor Antonio Scilimati's team developing novel therapeutics targeting Caseynolytic Protease P (ClpP) enzyme. ITEL donated research fellowship through Itelpharma division.
• Policlinico Gemelli (Rome)minorStrategic or Co-development Partner · 2 February 2021Pediatric oncology collaboration within DIPG research project network, including international partners (University of Washington, Kinderspital Zurich, UCSF).
• ENEA (Agenzia Nazionale per le Nuove Tecnologie)coreStrategic or Co-development Partner · 12 December 2019Protocol of understanding for cooperation on development of the first linear proton accelerator. ENEA collaboration on ERHA project research and development, combining ITEL industrial expertise with ENEA national research capabilities.
• University of Bari Aldo MorocoreStrategic or Co-development Partner · 1 January 2011Primary research partner for RAISE project (PON01_03054) optimizing 18F-DOPA radiotracer production processes. Joint patent development and academic research collaboration.
• University of SalentominorStrategic or Co-development Partner · 1 January 2011Research partner in RAISE project consortium for radiotracer production optimization.
• National Research Council (CNR)minorStrategic or Co-development Partner · 1 January 2011Research partner in RAISE project consortium for bioimaging innovation and radiopharmaceutical development.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Varian (a Siemens Healthineers company): Leading provider of proton therapy systems (ProBeam) and radiotherapy solutions, including patient positioning and treatment planning software. Directly comparable to ITEL on the proton therapy system side, particularly competing with ERHA and RPPS.
• IBA (Ion Beam Applications): World leader in proton therapy systems, supplying ProteusONE and ProteusPLUS proton therapy solutions to hospitals globally. Most direct competitor to ITEL's ERHA/LinearBeam linear proton accelerator effort and comparable in proton therapy robotics and treatment planning.
• Lantheus Holdings: Radiopharmaceutical-focused company specializing in diagnostic imaging agents including PYLARIFY (PSMA-PET agent for prostate cancer). Directly comparable to ITEL's 18F-JK-PSMA-7 offering and Itelpharma's PET tracer portfolio.
• Curium Pharma: Global radiopharmaceutical manufacturer producing PET and SPECT diagnostic tracers. Directly comparable to Itelpharma as a GMP-certified radiopharmaceutical producer serving hospitals and nuclear medicine departments, though at vastly larger geographic and operational scale.
• Eckert & Ziegler Strahlen- und Medizintechnik: German-based specialist in radiopharmaceuticals and radiation technology, offering isotope production, radiopharmaceutical contract manufacturing, and radiation therapy equipment. Directly comparable to Itelpharma's GMP radiopharmaceutical production and ERHA-adjacent radiation technology offerings.

Broad incumbents

• Philips Healthcare: Global medical technology company offering diagnostic imaging systems (PET/CT, MRI), radiation oncology solutions, and healthcare informatics. Broad incumbent comparable to ITEL Diagnostic's hospital imaging facility design business and competing with adjacent radiation therapy offerings.
• Cardinal Health Nuclear Pharmacy Services: Operates the largest radiopharmaceutical distribution network in the United States, providing unit-dose radiopharmaceuticals and PET agents to hospitals. Comparable distribution model to Itelpharma's hospital radiopharmaceutical distribution network, though at vastly larger scale.
• GE HealthCare: Major multinational offering PET/CT imaging systems, radiopharmaceuticals (via GE HealthCare Pharmaceutical Diagnostics), and diagnostic imaging facility solutions. Broad incumbent comparable to ITEL Diagnostic and ITELPHARMA's hospital customer overlap.
• Bayer (Radiology / Curium JV history): Global pharmaceutical and life sciences conglomerate with radiology business including contrast media and historical radiopharmaceutical operations. Comparable as a broad incumbent in diagnostic imaging with overlapping reach into hospital radiopharmacy channels.

Regional players

• Bracco Imaging: Italian-headquartered diagnostic imaging company producing contrast agents and imaging solutions globally. Comparable as another Italian medical imaging player with overlapping hospital customer base and GMP manufacturing capabilities, though focused on contrast media rather than radiotracers.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCDne6f-s37gvCWaTol9d55Q
• Facebookfacebook.com/gruppoitel
• LinkedInlinkedin.com/company/itel-telecomunicazioni
• Instagraminstagram.com/itel_corporate_group
• Xx.com/itel_group

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ITEL